Northwest Agriculture & Forestry University has described thiazolecarboxamidine compounds acting as NADH-ubiquinone oxidoreductase (complex I) inhibitors reported to be useful for the treatment of cancer.
In the March 2023 issue of Science Immunology, researchers working at the City of Hope National Medical Center reported on the discovery the mechanisms by which the spliced X-box–binding protein 1 (XBP1s) served essential functions in the IL-15-dependent survival of natural killer (NK) cells. Since XBP1s is known to play critical roles in MHCII expression, the unfolded protein stress response, and ultimately tumorigenesis, the study provided deep insights into the understanding of NK cell biology with translational potential.
Medical robotics startup Noah Medical Inc. is conducting a first-in-human clinical trial to assess the safety and feasibility of its Galaxy system to improve lung cancer diagnosis. The device received U.S. FDA clearance on March 1 for use in bronchoscopic visualization and accessing patient airways for diagnostic and therapeutic purposes.
Precision oncology startup Prana Thoracic Inc. closed a $3 million series A financing round aimed at advancing its minimally invasive lung tissue excision device for early treatment of lung cancer. The series A funds and a prior $3 million award from the Cancer Prevention & Research Institute of Texas are earmarked for product development and to support first-in-human clinical studies.
Shanghai Huilun Pharmaceutical Co. Ltd. has identified thiazle derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of cancer, viral infections and autoimmune diseases.
Adlai Nortye Pharmaceutical Co. Ltd. has identified Wnt signaling inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.
Researchers from the Centro Nacional de Investigaciones Oncológicas aimed to identify pathways that contribute to the metabolic reprogramming ability of cancer cells upon resistance to ataxia-telangiectasia-mutated (ATM) inhibition. Metabolism-centered CRISPR screening identified Kelch-like ECH-associated protein 1 (KEAP1), which is an oxidative stress sensor that controls the Nrf2-regulated antioxidant pathway, as a key factor involved in desensitizing cancer cells to ATM inhibition.
